On June, 13 Myovant Sciences Ltd. (MYOV) EPS Estimated At $-0.77

May 17, 2018 - By Russell Jones

On June, 13 WallStreet expected Myovant Sciences Ltd. (NYSE:MYOV)’s earnings report, according to RTT. After $-0.70 earnings per share was announced last quarter, analysts now see negative EPS growth of 10.00 % for Myovant Sciences Ltd.. Ticker’s shares touched $21.7 during the last trading session after 2.34% change.Myovant Sciences Ltd. has volume of 48,877 shares. Since May 17, 2017 MYOV has risen 79.46% and is uptrending. MYOV outperformed by 67.91% the S&P500.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases.The company has $1.35 billion market cap. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.Last it reported negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

There’s an important Myovant Sciences Ltd. (NYSE:MYOV) news published by Prnewswire.com. It’s an item titled: “Myovant Sciences and PERIOD. Inc. Launch Partnership Focused on Empowering Women to Elevate the Conversation …” on April 20, 2018.

Myovant Sciences Ltd. (NYSE:MYOV) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: